Adherence in the CAPRISA 004 tenofovir gel microbicide trial

AIDS and Behavior

Volumn 18, Issue 5, 2014, Pages 811-819

  Mansoor, Leila Essop ^a   Abdool Karim, Quarraisha ^a   Yende Zuma, Nonhlanhla ^a   MacQueen, Kathleen M ^a   Baxter, Cheryl ^a   Madlala, Bernadette T ^a   Grobler, Anneke ^a   Abdool Karim, Salim S ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Adherence; Adherence measures; Adherence support; Clinical trial; HIV prevention; Microbicides

Indexed keywords

ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GEL; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR; TOPICAL ANTIINFECTIVE AGENT;

ADMINISTRATION AND DOSAGE; ADULT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; CONTROLLED STUDY; COUNSELING; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; EPIDEMIOLOGY; FEMALE; FOLLOW UP; GEL; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INCIDENCE; INTRAVAGINAL DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MEDICATION COMPLIANCE; MOTIVATIONAL INTERVIEWING; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RURAL POPULATION; SEXUAL BEHAVIOR; SOCIOECONOMICS; SOUTH AFRICA; STATISTICS AND NUMERICAL DATA; TRANSMISSION; TREATMENT OUTCOME; URBAN POPULATION; VIROLOGY;

ADENINE; ADMINISTRATION, INTRAVAGINAL; ADULT; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; COUNSELING; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GELS; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MEDICATION ADHERENCE; MOTIVATIONAL INTERVIEWING; ORGANOPHOSPHONATES; RURAL POPULATION; SEXUAL BEHAVIOR; SOCIOECONOMIC FACTORS; SOUTH AFRICA; TREATMENT OUTCOME; URBAN POPULATION;

EID: 84899660657     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-014-0751-x     Document Type: Article

References (33)

1. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2012. Available from: Global report: UNAIDS report on the global AIDS epidemic 2012. Geneva: Joint United Nations Programme on HIV/AIDS2012. Accessed 25 Mar 2013.
2. Van Damme L, Ramjee G, Alary M, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 2002;360(9338):971-7.
3. Feldblum PJ, Adeiga A, Bakare R, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One. 2008;3:e1474.
4. Peterson L, Nanda K, Opoku BK, et al. SAVVY(R) (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS One. 2007;2(12):e1312.
5. Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9654):1977-87.
6. Halpern V, Ogunsola F, Obunge O, et al. Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria. PLoS One. 2008;3:e3784.
7. Van Damme L, Govinden R, Mirembe FM, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med. 2008;359:463-72.
8. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168-74.
9. Tolley EE, Harrison PF, Goetghebeur E, et al. Adherence and its measurement in phase 2/3 microbicide trials. AIDS Behav. 2010;14(5):1124-36.
10. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411-22.
11. Marrazzo J, Ramjee G, Nair G, et al., editors. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE study (MTN 003). Conference of Retroviral and Opportunistic Infections; 2013. Goergia World Congress Centre, Atlanta.
12. Reid SE, Reid CA, Vermund SH. Antiretroviral therapy in sub-Saharan Africa: adherence lessons from tuberculosis and leprosy. Int J STD AIDS. 2004;15(11):713-6.
13. Lagakos S, Gable A, editors. Methodological challenges in biomedical HIV prevention trials. Washington, DC: National Academies Press; 2008.
14. Gilead Sciences Inc. Investigators Brochure: tenofovir gel (GS-1278). 5th ed. Foster City: California Gilead Sciences; 2013.
15. Mayer KH, Maslankowski LA, Gai F, et al. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS. 2006;20(4):543-51.
16. Abdool Karim SS, Abdool Karim Q. Diverse approaches useful for microbicide trials. Nature. 2007;449(7158):24.
17. Fisher JD, Fisher WA, Rivet Amico K, et al. An information-motivation- behavioral skills model of adherence to antiretroviral therapy. Health Psychol. 2006;25(4):462-73.
18. Fisher JD, Fisher WA. The information-motivation-behavioural skills model. In: DiClemente RJ, Crosby RA, Kegler MC, editors. Emerging theories in health promotion practice and research. Jossey-Bass: San Francisco; 2002. p. 40-70.
19. Misovich S, Fisher J, Martinez T, et al. Predicting breast self-examination: a test of the information-motivation-behavioural skills model. J Appl Psychol. 2003;33:775.
20. Misovich S, Fisher J, Fisher W. Close relationships and HIV risk behaviour: evidence and possible underlying psychological processes. Gen Psychol Rev. 1997;1:72-107.
21. Carey MP, Carey KB, Weinhardt LS, et al. Behavioral risk for HIV infection among adults with a severe and persistent mental illness: patterns and psychological antecedents. Community Ment Health J. 1997;33(2):133-42.
22. Amico KR, Toro-Alfonso J, Fisher JD. An empirical test of the information, motivation and behavioral skills model of antiretroviral therapy adherence. AIDS Care. 2005;17(6):661-73.
23. Mannheimer SB, Morse E, Matts JP, et al. Sustained benefit from a long-term antiretroviral adherence intervention. Results of a large randomized clinical trial. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S41-7.
24. Ferrer RA, Morrow KM, Fisher WA, et al. Toward an information-motivation- behavioral skills model of microbicide adherence in clinical trials. AIDS Care. 2010;22(8):997-1005.
25. Fisher JD, Cornman DH, Norton WE, et al. Involving behavioral scientists, health care providers, and HIV-infected patients as collaborators in theory-based HIV prevention and antiretroviral adherence interventions. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S10-7.
26. Rollnick S, Miller WR. What is motivational interviewing? Behav Cogn Psychother. 1995;23:325-34.
27. Emmons KM, Rollnick S. Motivational interviewing in health care settings. Opportunities and limitations. Am J Prev Med. 2001;20(1):68-74.
28. Mansoor LE, Abdool Karim Q, Werner L, et al. Impact of an adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trial. AIDS Behav. 2014. doi: 10.1007/s10461-014-0752-9.
29. Mauck CK, Van de Straten A. Using objective markers to assess participant behavior in HIV prevention trials of vaginal microbicides. J Acquir Immune Defic Syndr. 1999;2008(49):64-9.
30. Austin MN, Rabe LK, Hillier SL. Limitations of the dye-based method for determining vaginal applicator use in microbicide trials. Sex Transm Dis. 2009;36(6):368-71.
31. Wallace AR, Teitelbaum A, Wan L, et al. Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials. Contraception. 2007;76(1):53-6.
32. Mngadi KT, Maarschalk S, Grobler AC, et al. Disclosure of microbicide gel use to sexual partners: influence on adherence in the CAPRISA 004 trial. AIDS Behav. 2014. doi: 10.1007/s10461-014-0696-0.
33. Woodsong C, MacQueen K, Amico KR, et al. Microbicide clinical trial adherence: insights for introduction. J Int AIDS Soc. 2013;16:18505.